Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 for Lymphopenia in PML
NCT04781309Phase 1Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- May 2021
- Primary completion
- Nov 2025
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of efineptakin alfa in progressive multifocal leukoencephalopathy (PML), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Absolute Lymphocyte Count at 6 months. Started May 2021; status: completed.
02
Drugs
efineptakin alfa
03
Conditions
progressive multifocal leukoencephalopathy (PML)
Beyond the preview
Go deeper on NCT04781309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781309.